Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Account Payables (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Change in Account Payables for 9 consecutive years, with $10.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 335.21% to $10.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.1 million, a 325.95% increase, with the full-year FY2025 number at $3.1 million, up 325.95% from a year prior.
  • Change in Account Payables was $10.4 million for Q4 2025 at Akebia Therapeutics, up from -$8.8 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $18.9 million in Q4 2022 to a low of -$13.8 million in Q3 2021.
  • A 5-year average of -$688000.0 and a median of -$1.8 million in 2022 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: crashed 272.51% in 2021, then soared 491.65% in 2022.
  • Akebia Therapeutics' Change in Account Payables stood at $3.2 million in 2021, then skyrocketed by 491.65% to $18.9 million in 2022, then plummeted by 76.2% to $4.5 million in 2023, then tumbled by 46.84% to $2.4 million in 2024, then surged by 335.21% to $10.4 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Change in Account Payables are $10.4 million (Q4 2025), -$8.8 million (Q3 2025), and $3.7 million (Q2 2025).